No Survival Advantage With Sacituzumab Over Chemo in Previously Treated NSCLC
Subcutaneous Amivantamab Plus Lazertinib Non-Inferior to IV Dosing in NSCLC
How Have Kids' Colorectal Cancer Rates Changed?
Novel Bispecific in EGFR-Mutant Lung Cancer Boosts PFS After Targeted Agents
Kinder, Gentler Regimen for Classical Hodgkin Prevails in Randomized Trial
Desktop versie